

CONTENTS

	page
COVER	i
APPROVAL PAGE	ii
TRIBUTE.	iii
STATEMENT OF AUTHENTICITY.	iv
ACKNOWLEDGEMENT.	v
CONTENTS	vii
TABLE LIST	x
FIGURE LIST	xi
APPENDIX LIST.	xii
ABBREVIATIONS.	xiii
ABSTRACT	xiv
CHAPTER I. INTRODUCTION	1
A. Background	1
B. Key Issues	2
C. Objectives	3
D. Significance of the Study	3
E. Research Authenticity	3
CHAPTER II. LITERATURE REVIEW	6
A. Literature Analysis	6
1. Antimicrobial Resistance	6
2. Pneumonia	9

3. Meropenem	12
4. Prolonged Beta Lactam Infusion	14
B. Theoretical Basis.	18
C. Conceptual Framework.	19
D. Hypothesis	20
CHAPTER III. RESEARCH METHODOLOGY	21
A. Research Design.	21
B. Research Setting.	23
C. Research Subject.	23
D. Research Variables	26
E. Operational Definitions.	27
F. Research Instrument.	30
G. Research Phases.	30
H. Data Analysis.	34
CHAPTER IV. RESULT AND DISCUSSION	35
A. Subjects Demographics.	36
B. Clinical Outcomes Comparison.	45
C. Confounding Factors Influence On The Outcomes of The Study.	52
D. Limitations.	54
CHAPTER V.CONCLUSION AND SUGGESTION.	55
A. Conclusion.	55
B. Suggestions.	55
REFERENCES	57

APPENDICES.....	69
THESIS SUMMARY.....	96
PUBLICATION DRAFT.....	108

TABLE LIST

	page
Table 1. List of Known Bacterial Intrinsic Resistances to Antibiotics.	7
Table 2. List of Common CAP Related Pathogens	11
Table 3. Meropenem Dosing Recommendations for Prolonged / Extended Infusion.	18
Table 4. Operational Definition of Variables.	27
Table 5. Parameters Interpretation.	29
Table 6. Demographic and Baseline Characteristics.	38
Table 7. Treatment Success Rate.	45
Table 8. APACHE II Score Comparison Between Pre-Meropenem Therapy and 72-Hours After The First Meropenem Dose. . .	49
Table 9. Time to Infection Resolution (Days).	50
Table 10. Duration of Meropenem Therapy (Days).	50
Table 11. The Influence of Confounding Factors on Treatment Success Rate by Logistic Regression.	52
Table 12. The Influence of Confounding Factors on Days to Infection Resolution by Kruskal-Wallis Test.	54

FIGURE LIST

	page
Figure 1. Conceptual Framework	19
Figure 2. Research Variables.	26
Figure 3. Research Phases Flowchart.	33
Figure 4. Flowchart of Subjects Selection.	37

APPENDIX LIST

Appendix 1.	Ethical Clearance	66
Appendix 2.	Hospital Permit.	67
Appendix 3.	Subjects Data.	69
Appendix 4.	Statistical Analysis.	74

ABBREVIATIONS

ADR	: Adverse Drug Reaction
AMR	: Antimicrobial Resistance
APACHE II	: Acute Physiology and Chronic Health Evaluation II
AUC	: Area Under Curve
CAP	: Community Acquired Pneumonia
CCI	: Charlson Comorbidity Index
HAP	: Hospital Acquired Pneumonia
ICU	: Intensive Care Unit
MDRO	: Multiple Drug Resistant Organism
MIC	: Minimum Inhibitory Concentration
PBPs	: Penicillin-Binding Proteins
PCV	: Pressure Controlled Ventilation
PSI	: Pneumonia Severity Index
PSV	: Pressure Support Ventilation
RND	: Resistance Nodulation Cell Division
SIMV	: Synchronous Intermittent Mandatory Ventilation
SMR	: Small Multidrug Resistance
VAP	: Ventilator Associated Pneumonia
WBC	: White Blood Cells